Derik de Bruin

10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenues Thursday that were meaningfully below the consensus estimates. While the miss was due to several factors, the most significant was China’s COVID-19 related lockdowns that led to the closure of academic labs,...

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities. The Ginkgo Bioworks Analyst: Derik de Bruin downgraded the rating for...

NeoGenomics, Inc. (NASDAQ: NEO) shares are getting hammered Tuesday after the cancer diagnostics company announced the abrupt resignation of CEO Mark Mallon and warned of the first-quarter shortfall while also withdrawing its full-year guidance. The NeoGenomics Analyst: BofA...

It can be fun to trade meme stocks, speculate on penny stocks and take a gamble on high-risk stocks that could be 10-baggers in a couple of years. However, investors buying stocks for their 401(k) or other retirement accounts should be looking for an entirely different type of investment. The best...

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities. The Ginkgo Bioworks Analyst: Derik de Bruin initiated coverage of Ginkgo Bioworks with a Buy rating and $8 price...

The COVID-19 environment may boost Qiagen's (NYSE: QGEN) new products, like QIA-STAT and NeuMoDx, according to BofA Securities. The Qiagen Analyst: Derik de Bruin reinitiated coverage of with a Buy rating and a price target of $59. The Qiagen Thesis: Although Thermo Fisher Scientific Inc. (NYSE...

Quest Diagnostics Inc (NYSE: DGX)  preannounced its second-quarter revenue at around $1.83 billion on Monday, beating Street estimates by about 18%. Preliminary also came in ahead, in the range of $1.39-$1.42 per share versus the Street’s 18-cent estimate.  The company...

Overall, 2019 was a huge year for the stock market, and there were plenty of high-profile IPOs throughout the year as well. Unfortunately, some of the most eagerly anticipated IPOs of the past year ended up being flops for investors. But now that the excitement and volatility associated with 2019...

DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ: ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.  The Analyst Derik de Bruin downgraded Illumina from...

Guardant Health Inc (NASDAQ: GH) is off to a red-hot start to 2019, but one analyst says the rally may be just getting started. The Analyst Bank of America analyst Derik de Bruin upgraded Guardant from Neutral to Buy and raised his price target from $81 to $84. The Thesis While se Bruin says...

An 8-K filed late Wednesday suggests Hologic, Inc. (NASDAQ: HOLX)’s headed for harder times. The Analyst Bank of America Merrill Lynch analyst Derik de Bruin downgraded Hologic from Buy to Neutral and cut the price target from $47 to $42. The Thesis Hologic subsidiary...

Despite negative projections immediately following the Quintiles-IMS Holdings merger in 2016, Iqvia Holdings, Inc. (NYSE: IQV) is showing growth, according to Bank of America Merrill Lynch.  The Analyst Analyst Derik de Bruin on Wednesday upgraded Iqvia Holdings from Neutral to Buy and...

Reviewing the fiscal year fourth-quarter results of Catalent Inc (NYSE: CTLT), the sell side exuded optimism concerning the company. Bank of America Merrill Lynch said the company has had a strong finish to its best year since IPOing, while Wells Fargo Securities said momentum at the company...

IDEXX Laboratories, Inc. (NASDAQ: IDXX) hosted last week its annual Analyst Day presentation which prompted analysts at Bank of America to upgrade the stock and label it a "top dog." The firm's Derik de Bruin upgrades Idexx's stock rating from Neutral to Buy with an unchanged $175...